However, ipilimumab combined with chemotherapy and PD-L1 inhibitors has demonstrated encouraging outcomes in both preclinical and clinical research.57 A phase I trial called CheckMate-012 (NCT03527251) assessed the effectiveness of ipilimumab plus nivolumab in untreated NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.